Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy

Caribou Biosciences

31/03/2026 13:22

** Shares of biotech firm Caribou Biosciences CRBU.O rise about 9% to $1.88 premarket

** Co says the FDA granted Regenerative Medicine Advanced Therapy (RMAT) status to its experimental cell therapy CB‑011 for multiple myeloma, a blood cancer that affects plasma cells in bone marrow

** The RMAT designation is designed to expedite the review of promising therapeutic candidates for an unmet medical need

** Co says early‑stage study data showed the therapy met its main goal of shrinking cancer signs in heavily pre‑treated patients

** Adds, 12 patients who had not received similar treatments showed a 92% overall response rate, with 75% seeing cancer signs disappear or nearly disappear

** Says CB‑011 is designed as an “off‑the‑shelf” gene‑edited cell therapy, which could reduce long wait times linked to current treatments

** Co says the trial is ongoing and more data are expected in 2026

** Multiple myeloma is a cancer of infection‑fighting blood cells that crowd out healthy cells, leading to bone damage, low immunity and fatigue

** As of last close, stock up ~8% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))